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Abstract
Background: The neural transcription factor SOX11 has been described as a prognostic marker in epithelial ovarian
cancers (EOC), however its role in individual histological subtypes and tumour grade requires further clarification.
Furthermore, methylation-dependent silencing of SOX11 has been reported for B cell lymphomas and indicates
that epigenetic drugs may be used to re-express this tumour suppressor, but information on SOX11 promoter
methylation in EOC is still lacking.
Methods: SOX11 expression and clinicopathological data was compared using c
2 test in a cohort of 154 cases of
primary invasive EOC. Kaplan-Meier analysis and the log rank test were applied to evaluate ovarian cancer-specific
survival (OCSS) and overall survival (OS) in strata, according to SOX11 expression. Also, the methylation status of the
SOX11 promoter was determined by sodium bisulfite sequencing and methylation specific PCR (MSP). Furthermore,
the effect of ectopic overexpression of SOX11 on proliferation was studied through [3H]-thymidine incorporation.
Results: SOX11 expression was associated with an improved survival of patients with high grade EOC, although not
independent of stage. Further analyses of EOC cell lines showed that SOX11 mRNA and protein were expressed in
two of five cell lines, correlating with promoter methylation status. Demethylation was successfully performed using
5’-Aza-2’deoxycytidine (5-Aza-dC) resulting in SOX11 mRNA and protein expression in a previously negative EOC cell
line. Furthermore, overexpression of SOX11 in EOC cell lines confirmed the growth regulatory role of SOX11.
Conclusions: SOX11 is a functionally associated protein in EOC with prognostic value for high-grade tumours. Re-
expression of SOX11 in EOC indicates a potential use of epigenetic drugs to affect cellular growth in SOX11-
negative tumours.
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Background
E O Ci sah e t e r o g e n e o u sd i s ease compromising many
histological subtypes including clear cell, mucinous,
endometrioid and serous carcinoma, which are sub-
classified into high- and low-grade [1]. Differences in sur-
vival between the histological subtypes have been
observed, with mucinous and endometrioid carcinomas
having a more favourable prognosis compared to high
grade serous [2] and clear cell carcinomas [3], most likely
related to distinct differences in tumour biology [4]. It
has been emphasized that each EOC subtype needs to be
considered separately in order to identify clinically rele-
vant biomarkers [5]. EOC, and the clear cell subtype in
particular, is known to only initially be responsive to che-
motherapy treatment [6] and the main prognostic factor
remains surgical debulking status [7,8]. This emphasizes
that targeted therapies, potentially specific for each sub-
type, are needed in combination with improved methods
for early detection. To identify the biology underlying
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gets, gene expression profiling has been used [9,10].
Among others, a new subtype of high grade serous can-
cer reflecting a mesenchymal cell type, characterized by
low expression of MUC1, has been identified. This new
subgroup has an undifferentiated phenotype and
expresses developmentally associated transcription fac-
tors, including SOX11, as well as other high-mobility
group members such as HMGA2, TOX and TCF7L1
[11].
SOX11 is a diagnostic and prognostic antigen in B cell
lymphomas [12-17] and has recently been demonstrated
by us to have tumour suppressor functions [18]. This
transcription factor is also a prognostic antigen in EOC,
where its presence is associated with improved recur-
rence-free survival (RFS) [19]. In the present study, we
confirm the relationship between SOX11 and survival in
EOC, although a larger set of endometrioid cancer needs
to be investigated to show independent prognostic rele-
vance. To identify suitable in vitro models for functional
analyses, EOC cell lines were screened for SOX11 expres-
sion and promoter methylation was assessed in both
positive and negative cell lines. To verify that methylation
is a key event in silencing SOX11, 5-Aza-dC treatment
was used to re-express SOX11 in an in vitro model of
EOC. Furthermore, the tumour suppressor function of
SOX11, as previously reported for B cell lymphomas [18],
was now extended to EOC and demonstrated through
transient over-expression of SOX11.
In summary, we show that SOX11 is a prognostic and
functional antigen associated with improved survival in
high grade EOC. Furthermore, specific promoter methy-
lation was shown to be a key event in silencing SOX11.
Methods
Clinical material and construction of tissue microarrays
T h et i s s u em i c r o a r r a y( T M A )w a sc o n s t r u c t e df r o ma
consecutive cohort of 154 cases of primary invasive EOC
from the prospective, population based cohorts Malmö
Diet and Cancer [20] and Malmö Preventive Medicine
[21]. The histological re-evaluation of the joint cohort
and construction of the TMA has previously been
described by Ehlén et al. [22]. The patient cohort is sum-
marised in Table 1. All national and international guide-
lines including the Helsinki Declaration on ethical
principles for medical research involving human subjects,
i.e. Declaration of Helsinki - Ethical Principles for Medi-
cal Research Involving Human Subjects (2000) were
applied during the project.
Immunohistochemical analysis of SOX11
TMA sections were pre-treated as previously described
[19]. Immunohistochemistry (IHC) was performed, using
the primary rabbit anti-human SOX11
C-term antibody
[13], according to a previous staining protocol [19].
Briefly, signal was detected, using the Dako REAL Detec-
tion system and slides were counterstained with Mayers
hematoxylin (Sigma-Aldrich, St Louis, MO).
Image Acquisition, Management and Automated analysis
and statistical analysis
The Aperio ScanScope XT Slide Scanner (Aperio Tech-
nologies, Vista, CA) system was used to capture whole
slide digital images with a 20X objective and nuclear
SOX11 expression was automatically quantified. A tumor
specific nuclear algorithm (IHC -MARK) was developed in
house to quantify SOX11 protein expression. IHC-MARK
was designed to identify tumor cells on the basis on
nuclear morphology and disregard non-tumor cells such
as normal epithelial or stromal cells, or invading leuko-
cytes as previously described [23]. The algorithm calcu-
lated the percentage of positive tumor cells, as well as
relative staining intensity ranging from 0 to 255. Patients
were divided into subgroups having either higher or lower
than 10% nuclear SOX11 expression. Statistical analysis
was performed, as previously described [19]. Briefly, the c
2
test was used for comparison of SOX11 expression and
clinicopathological data, and Kaplan-Meier analysis and
the log rank test were applied to evaluate and illustrate
ovarian cancer specific survival (OCSS) and overall
Table 1 Clinicopathological characteristics in the total
cohort and the SOX11 positive subgroup
Histology N total (%)
1 N SOX11 positive (%)
2
Total 154 55
Histological subtype
Mucinous 12 (8)
1 3 (5)
Serous 90 (58) 31 (56)
Endometrioid 35 (23) 17 (31)
Clear cell 9 (6) 0
Brenner 1 (0.6) 0
Unknown 7 (5) 4 (7)
Grade
High
3 107 (70) 40 (73)
Low
4 47 (30) 15 (27)
Stage
I 26 (17) 10 (18)
II 18 (12) 9 (16)
III 75 (49) 26 (47)
IV 22 (14) 5 (9)
Unknown 13 (8) 5 (9)
1The percentage is based on the total number of cases.
2 The percentage is based on the total number of SOX11 positive cases.
3 High grade includes cases with low differentiation grade
4 Low grade includes cases with intermediate and high differentiation grade.
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Cox regression proportional hazards models were used to
estimate the relationship between SOX11 expression in
high grade tumours and stage. All calculations were per-
formed, using SPSS version 11.0 (SPSS Inc, Chicago, IL).
Cultivation of EOC cell lines
In total, five different EOC cell lines (Table 2) were used in
the study: TOV-112D, derived from malignant solid
epithelial ovarian tumour specimens [24], NIH:OVCAR-3,
originating from the malignant ascites of a patient with
progressive adenocarcinoma [25], ES-2 [26], A2780 and
A2780-CP7 [27]. The cell line TOV-112D was cultured in
DMEM High Glucose media (Hyclone, South Logan,
Utah, USA) supplemented with 15% fetal bovine serum
(FBS) and 1% L-glutamin (both Invitrogen, Carlsbad, CA,
USA). OVCAR-3 was maintained in RPMI-1640 media
(HyClone) supplemented with 20% FBS, 1% L-glutamin
and 0,01 mg/ml insulin (Sigma-Aldrich). A2780 and
A2780-CP7 were maintained in RPMI-1640 media supple-
mented with 10% FBS and 1% 200 mM L-glutamine. ES-2
was cultured in McCoy’s 5A media (HyClone) supplemen-
ted with 10% FBS.
RNA isolation and quantitative real time PCR
The relative quantity (RQ) of SOX11 mRNA in various cell
lines was identified using Real Time-quantitative PCR
(qRT-PCR). The cells were lysed and cDNA synthesis per-
formed using the Fast SYBR Green Cells-to-CT kit and
the samples were run on a Fast 7500 qRT-PCR system
(Applied Biosystems, Foster City, CA, USA), as previously
described [18]. Briefly, 30 000-50 000 cells were washed in
PBS, lysed and treated with DNase. Lysates were reversed-
transcribed and cDNA amplified in three technical repli-
cates with the following primer specific either for SOX11
or the house-keeping gene GAPDH (the concentration
was 250 nM (MWG, High-Point, NC, USA)); GAPDH: 5’-
TGGTATCGTGGAAGGACTC-3’ and 5’-AGTAGAGG-
CAGGGATGATG-3’, SOX11:5 ’-GGTGGATAAG-
GATTTGGATTCG-3’ and 5’-GCTCCGGCGTGCAGT
AGT-3’. The RQ is calculated as 2
-(ΔΔCT(SOX11-GAPDH)).
For analysis of absolute levels of SOX11, a control sample
was run, containing lysate but no reverse transcriptase
(RT), enabling estimation of amplification above genomic
level, as previously described [18]. Generally, all samples
with a ΔCT (SOX11+RT, SOX11-RT) < |2|, here after referred to
as ΔCT,SOX11, were considered negative. All the error bars
related to qRT-PCR data have been calculated using the
standard error (SE) value with a 95% confidence interval.
Protein purification and quantification
Protein was extracted and quantified as previously
described [18]. Briefly, 0.2 to 8 million cells were harvested,
washed and placed in 200 μl lysis-buffer (1% Ipegal/Pro-
tease Inhibitor cocktail (Roche, Basel, Switzerland) in PBS).
Western Blot analysis of SOX11-knockdown and
differential expression
Protein lysates, 43 μg for wild-type expression, lysates of
0.2 million cells for demethylation and 30 μgf o ro v e r e x -
pression, from five ovarian cancer cell lines were run on
NuPAGE 10% Bis-Tris gels (Invitrogen, Carlsbad, CA,
USA) under reducing conditions for ~45 min at 130 V.
Separated proteins were blotted on PVDF iBlot Transfer
stacks in the iBlot gel transfer device (both Invitrogen) and
blocked for 1 h. SOX11 protein expression was verified
using an antibody targeting SOX11 (Atlas Antibodies,
Stockholm Sweden) and a HRP-labelled swine anti-rabbit
antibody (DAKO, Glostrup, Denmark) as secondary anti-
body. Blots were developed, using the SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce, Thermo
Scientific, Waltham, MA, USA), according to the protocol
of the manufacturer, detected in a CCD-camera and
analysed in the Quantity One software (both Bio-Rad,
Hercules, CA, USA).
Analysis of promoter methylation status
The methylation status of the SOX11 promoter was
determined by sodium bisulfite sequencing and MSP.
Briefly, DNA was extracted from the cell lines with
QIAamp DNA Mini Kit (QIAgen, Hilden, Germany). 0.5-
1 μg of DNA was bisulfite converted with QIAgen Epitect
Bisulfite Kit (QIAgen) and 50-100 ng of converted DNA
w a su s e da st e m p l a t ei nt h eP C R .E p i t e c tC o n t r o lD N A
(QIAgen) was used as controls in all PCR reactions to
ensure specific PCR amplification using Platinum Taq
DNA polymerase (Invitrogen). For bisulfite sequencing,
primers that amplified a 213 bp region containing 28
CpG’s adjacent to the 5’ end of the SOX11 transcription
start site were used as previously described [18]. PCR
products were directly sequenced by Eurofins MWG
Operon (Ebersberg, Germany). Clonal analysis of indivi-
dual alleles was made by subcloning the PCR fragments
into pCR.21-TOPO vector (Invitrogen) and transformed
into chemically competent E.coli TOP10 (Invitrogen).
MSP was performed with primers specific for methylated
Table 2 EOC Cell line characteristics
Cell line Disease
TOV-112D
1 Primary malignant adenocarcinoma
OVCAR-3
3 Progressive adenocarcinoma
ES-2
1 Poorly differentiated ovarian clear cell carcinoma
A2780
2 Undifferentiated CA
A2780-CP7
2 Undifferentiated CA
1 - Kindly provided by Gabriella Honeth, Department of oncology, Lund
University.
2 - Kindly provided by who Prof R Brown, Imperial College, London.
3 - American Type Culture Collection (ATCC).
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region as the bisufite sequencing primers. The primers
were 5’-TAG TCG CGT TTT TAA ATA TTA TCG A-3’
(M-fwd) 5’-CCT AAC CGA CGA AAA ATA ACG-3’ (M-
rev) and 5’-TAG TTG TGT TTT TAA ATA TTA TTG A-
3’ (U-fwd) 5’-ACC CTA ACC AAC AAA AAA TAA CAC
T-3’ (U-rev). PCR products were analyzed on a 2% agar-
ose gel.
Demethylation experiments using 5’-Aza-2’deoxycytidine
To perform demethylation experiments, the ovarian can-
cer cell line ES-2 that is methylated in the SOX11 pro-
moter was used. ES-2 was seeded and grown o/n until
60% confluency. 5-Aza-dC (Sigma Aldrich, St. Louis,
MO, USA) was applied (2μMo r1 0 μM) to the wells
together with fresh media every 24
th hours. Equivalent
amount of media was added to mock-treated cells. After
96 hours the cells were harvested by trypsination. DNA
and protein was extracted as above. Quantification of
DNA and protein was performed using the volume mea-
surement (Intensity*Area) and global background sub-
traction in Quantity One software (Bio-Rad). For DNA
quantification, the total volume of pairwise DNA samples
(treated and untreated control samples) was set to 100%.
For protein quantification, the relative volume of
untreated control sample was set to 1.
Overexpression of SOX11 in EOC cell lines
Transfection of the cells to overexpress SOX11 was per-
formed following the Lipofectamine™ 2000 protocol
(Invitrogen). Briefly, one to two days prior to transfection
50 000 - 100 000 cells/cm
2 from each cell line were seeded
into culture vessels. Transfection was performed with the
SOX11-GFP plasmid, OmicsLink™ Expression Clone, EX-
M0425-M46 (GeneCopoeia™), in one culture vessel and
with the GFP plasmid; OmicsLink™ Expression Clone,
EX-EGFP-M02 (GeneCopoeia™); in another with a DNA
(μg):Lipofectamine™ 2000 (μl) ratio of 1:2.5. 24 hours
after transfection the cells were harvested and samples
were taken for mRNA, protein and proliferation assays.
Proliferation assay using [methyl-3H]-thymidine
incorporation and assessment of confluency
The proliferation assays were performed using [methyl-
3H]-thymidine incorporation. 15000 cells were seeded in
triplicates onto 96-well plates, left for a couple of hours
for the cells to attach, then [3H]-thymidine (1 mCi/ml,
5 Ci/mmol, Amersham, GE Healthcare) was added and
the cells were incubated for 8-16 hours. Cells were then
frozen and finally thawed and harvested in a Tomtec Har-
vester 96 (Tomtec, Hamden, CT, USA) and analysed with
a 1450 MICROBETA liquid scintillation counter (Wallac
(now PerkinElmer
®, Waltham, MA, USA)). To assess con-
fluency, treated and control cell lines were photographed
48 h after overexpression of SOX11 using a Fluovert FS
inverted microscope (Leitz, MI, United States) with 32×
magnification and a Nikon Coolpix 995 digital camera
(Nikon, Tokyo, Japan).
Results
SOX11 expression and correlation to survival in high
grade and endometrioid carcinomas
SOX11 was recently discovered to be a diagnostic
[12-14,16], prognostic [15,17] and functionally associated
antigen [18] in B cell lymphomas, but also of prognostic
value in EOC [19]. To further investigate the importance
of SOX11 expression in EOC, we used a large TMA com-
prising different histological variants, such as mucinous,
serous, endometrioid and clear cell [22,28]. A tumor speci-
fic nuclear algorithm (IHC-MARK) was developed and
used to evaluate the nuclear SOX11 protein expression. A
representative IHC staining showing nuclear expression of
SOX11 is shown in Figure 1a. Kaplan Meier estimates
demonstrated an association between SOX11 nuclear
expression and an improved cancer-specific survival in
high grade EOC (p = 0.047) (Figure 1b). Multivariate ana-
lysis demonstrated a co-dependence with stage. Analysis
of SOX11 expression in relation to histological subtypes
revealed a non-significant trend towards an improved
overall survival (OS) within the endometrioid subtype (p =
0.066) (data not shown)). In contrast to previous data
where SOX11 mRNA was shown to specifically be
expressed in high grade serous cancer [11], our analyses
showed no correlation between SOX11 status and distri-
bution of high and low grade tumours in individual histo-
logical subtypes (data not shown).
SOX11 promoter methylation status correlates to mRNA
and protein expression
In an attempt to understand the functional implications of
SOX11 expression in EOC, we analysed the expression of
both SOX11 mRNA and protein in five different EOC cell
lines. TOV-112D and OVCAR-3 were shown to have sig-
nificant levels of SOX11 expression (Figure 2) as com-
pared to the other cell lines. Of interest, TOV-112D is of
endometrioid origin and the expression of SOX11 in this
cell line is consistent with the presence of primary
SOX11-positive endometrioid tumours (Table 1). The ori-
gin of OVCAR-3, which also expressed SOX11, is unfortu-
nately not known. To determine the methylation status of
the SOX11 promoter in all five EOC cell lines sodium
bisulfite sequencing was used. 28 CpG’si nt h eS O X 1 1
promoter were analysed (Table 3) and the percentage of
methylated CpG’sc a l c u l a t e d( F i g u r e2 ) .T h et h r e ec e l l
lines A2780, A2780-CP7 and ES-2 were highly methylated
which correlated with a complete lack of SOX11 expres-
sion at both mRNA and protein level. The two cell lines
TOV-112D and OVCAR-3, on the other hand, were
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expression of SOX11 at both the mRNA and protein level.
Demethylation of ovarian cancer cell line ES-2 induced
SOX11 mRNA and protein expression
The SOX11 negative epithelial ovarian cancer cell line
ES-2 is methylated in the SOX11 promoter region. In
order to demonstrate that the methylation is responsible
for silencing of the SOX11 gene, this cell line was trea-
ted with the demethylating agent 5-Aza-dC. Treatment
of ES-2 with 2 and 10 μM 5-Aza-dC for 96 hours
resulted in demethylation of the SOX11 promoter
(Figure 3A). Quantification showed an increase from 8%
(untreated control) to 57% (2 μM 5-Aza-dC) and 82%
(2 μM 5-Aza-dC) unmethylated DNA. This was accom-
panied by an immediate upregulation of SOX11 mRNA
(Figure 3B). Also analysis on the protein level confirmed
expression of SOX11 and quantification showed a 4.6
and 3.5 fold increase in protein level comparing treated
(2 and 10 μM 5-Aza-dC, respectively) with untreated
samples (Figure 3C). Analysis of the absolute levels of
SOX11 in wt SOX11-positive and negative EOC cell
lines showed that TOV-112D and OVCAR-3 had a ΔCT,
SOX11 of 5.4 and 7.0 respectively, while ΔCT,SOX11 were
<1.0 for the negative cell lines. Thus, it is clear that the
demethylation resulted in significant amounts of SOX11,
but at a level lower than the wt positive cell lines. Thus,
SOX11-negative ovarian cancer cell lines are specifically
Figure 2 Promoter methylation of SOX11 correlates to mRNA
and protein expression in EOC cell lines. The relative mRNA
levels (RQ) as compared to OVCAR-3 are shown as diamonds. The
standard deviation for the RQ values has been calculated with a
95% confidence interval (CI). Below, corresponding protein levels are
shown. The degree of SOX11 promoter methylation, described as
percentage of methylated CpGs of 28 possible CpG methylation
sites, is shown as bars. The three cell lines A2780, A2780-CP7 and
ES-2 all lack mRNA and protein expression of SOX11, correlating to
a high percentage of methylated CpG sites.
Figure 1 IHC and survival analyses of SOX11. (A) Representative nuclear SOX11 staining identified using an automatic tumor specific
algorithm showing nuclear expression in red. (B) Kaplan-Meier analysis and the log rank test identified SOX11 as significant associated (p =
0.047) with cancer specific survival in high grade tumours, including tumours with low differentiation grade. The patients were classified into two
groups based on SOX11 expression.
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reversed by demethylating drugs.
Overexpression of SOX11 in EOC cell lines
To further evaluate the functional role of SOX11 the gene
was overexpressed in five different EOC cell lines, by
transfecting them with a SOX11-GFP plasmid (Omic-
sLink™ Expression Clone). Transfection efficiency was
40-90%, measured as GFP positive control cells in flow
cytometry (data not shown). Both mRNA and protein
extracts were analysed by qRT-PCR and western blot to
confirm an overexpression of SOX11. Furthermore, the
proliferation of the cells was assessed by thymidine incor-
poration. The level of overexpression at mRNA level
varied between a 100-fold (A2780) to a 50000-fold
(A2780-CP7). For most cell lines the increase in mRNA
was also translated into an overexpression of the SOX11
protein. However, the 1000-fold increase of mRNA in
OVCAR-3 only resulted in a limited increase of SOX11
protein (Figure 4A). Using light microscopy to investigate
the confluency of the cell lines, it was evident that the
induction of SOX11 overexpression resulted in a signifi-
cant decrease in cell number (Figure 4B), as compared to
the control. Furthermore, the overexpression of SOX11
resulted in a decrease in proliferation in all cell lines
(Figure 4C). There was not a linear correlation between
level of overexpression and reduction in cell proliferation.
Among others, OVCAR-3, with a modest increase of
SOX11 protein responded with >50% reduced prolifera-
tion, while A2780-CP7, with the strongest overexpression
showed a lower decrease in growth rate. The difference in
response to SOX11 overexpression comparing different
cell lines may be related to the need of co-factors, as the
strongest effect was seen in cell lines which already
expressed SOX11, as also has been reported for B cell lym-
phomas [18].
Discussion
SOX11 has previously been identified as a prognostic anti-
gen in EOC, where SOX11 expression was associated with
a prolonged recurrence free survival [19]. In this study, we
demonstrated that SOX11 was associated with an
improved survival among patients with high-grade carci-
nomas and potentially also with endometrioid carcinomas,
although the latter needs to be statistically confirmed in a
larger cohort of patients. It is well known that EOC consti-
tutes a diverse set of malignancies, each with a separate
histology, gene expression pattern [29] and outcome
tightly linked to the underlying biology [4]. It has been
shown that low malignant potential tumours often pro-
gress to low grade serous carcinomas but that high grade
tumours rapidly develop from surface epithelium without
evidence of previous lesion [30]. This is consistent with a
stepwise mutation process (low-grade pathway) or a
greater genetic instability (high-grade pathway), as pre-
viously reviewed [31]. It is of major interest that SOX11
can be used to further subdivide high grade tumours,
which also indicates a functional role for SOX11 as a
tumour suppressor. It is not clear whether SOX11 defines
endometrioid carcinoma of a specific origin, since it has
been suggested that they, like clear cell ovarian cancer,
may be derived from endometriotic deposits in contrast to
the surface epithelial layer of the ovary or distal fallopian
tube [32]. Of importance, SOX11 is expressed in early pro-
genitor human multipotent stromal cells but expression
decreases with expansion of the cells [33]. Further studies
are needed to determine if SOX11 also is associated with
differentiation pattern in endometrioid carcinomas,
although they are known to mostly be well differentiated
[34], in contrast to our cohort. Preliminary, no association
with differentiation grade of endometrioid carcinomas and
SOX11 expression was seen, although the number of
patients was limited. More apparent, SOX11 expression
Table 3 Methylation status of individual CpGs in EOC cell
lines
Cog position A2780 A2780-CP7 ES-2 TOV-112D OVCAR-3
CpG1 NA
1 NA UM UM NA
CpG2 NA NA NA UM NA
CpG3 M
2 NA UM UM NA
CpG4 UM
3 NA UM UM NA
CpG5 MM M UM M
CpG6 MM M UM UM
CpG7 MM UM UM UM
CpG8 MM M UM UM
CpG9 MM UM UM UM
CpG10 MM M UM UM
CpG11 MM UM UM UM
CpG12 MM UM UM UM
CpG13 MM M UM UM
CpG14 MM M UM UM
CpG15 MM UM UM UM
CpG16 MM M UM UM
CpG17 MM M UM UM
CpG18 M NA M UM UM
CpG19 NA MM UM UM
CpG20 MM M UM UM
CpG21 MM M UM UM
CpG22 MM M UM UM
CpG23 MM M UM UM
CpG24 MM M UM UM
CpG25 MM M UM UM
CpG26 MM M UM UM
CpG27 MM M UM UM
CpG28 MM M UM UM
1NA - sequence data not available.
2M - methylated CpG positions are shown in bold.
3UN - unmethylated CpG positions.
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ever most SOX11 positive cases were found in the serous
and endometrioid subtypes. Correlation to the in vitro
models could not be performed as the majority of these
are poorly characterized. Some of the cell lines we used
have previously been xenografted into nude mice to ana-
lyse the resulting pathologies [27], but no firm conclusion
can be drawn between any correlation of SOX11 and their
potential histological subtype.
As previously shown for B cell lymphoma cell lines
[18], the protein and mRNA expression of SOX11 in
ovarian cancer cell lines correlated with the methylation
status of the SOX11 promoter region. Given the tumour
suppressor function of SOX11 [18] and the association
with cell cycle status [35], which has been demonstrated
previously by us in lymphomas, it is not surprising that
the promoter region of SOX11 in some EOC cell lines
becomes methylated in order to silence gene expression.
In ovarian cancer cell lines, knock-down of DNMT1 and
DNMT3b, resulting in loss of CpG hypermethylation, has
a negative effect on growth [36]. The specific methylation
of tumour suppressors is a known event in many differ-
ent cancers and is commonly studied by forced demethy-
lation through agents such as 5-Aza-dC, that inhibit the
DNA methyl transferases (DNMT’s) [37,38] and subse-
quent analysis of expression of target genes. Here, we
were able to demethylate the SOX11 promoter in the
ovarian cancer cell line ES-2, resulting in a successful
expression of SOX11 mRNA and protein. However, the
level of SOX11 expression upon demethylation was sig-
nificantly lower compared to SOX11 wt positive control
cell lines such as TOV-112D and OVCAR-3. Probably,
there are additional epigenetic factors besides an
unmethylated promoter that are needed to reach the
endogenous levels of wt SOX11 expression. Others have
recently shown that SAHA treatment used in combina-
tion with 5-Aza-dC increase the expression of SOX11 in
a negative B cell lymphoma cell line [39]. In ovarian can-
cer, platinum-resistance is a common problem and it has
been proposed that this might in part be explained by
hypermethylation and other epigenetic events that
repress tumour suppressor genes in general [40]. Thus,
the successful use of DNMT and HDAC (Histone deace-
tylases) inhibitors for chemotherapy re-sensitization in
ovarian cancer cell lines and animal models imply that
epigenetic therapies could be a future method for clinical
chemo re-sensitization [40]. This is also supported by our
data where forced SOX11 expression leads to a reduced
proliferation.
Of interest, the clinical outcome of patients afflicted by
EOC has been associated to differential expression of cell
cycle regulatory proteins including Cyclin D1, Cyclin E,
p16-INK and E2F transcription factors [41]. We have
previously shown that some oft h e s ep r o t e i n s ,i n c l u d i n g
p16INK, Rb and E2F transcription factors [18] change
their expression, as a result of overexpression of SOX11
in lymphoma cell lines and these genes may thus be
responsible for the improveds u r v i v a la s s o c i a t e dw i t h
SOX11-positive tumours also in EOC.
Conclusions
In the present study, SOX11 was demonstrated to be of
prognostic value for high grade EOC, which could have
a clear clinical value. The possibility to re-express
Figure 3 Induced expression of SOX11 in ES-2. (A) Treatment of the ovarian cancer cell line ES-2 with 5-Aza-dC for 96 h led to demethylation
of the SOX11 promoter. (B) SOX11 mRNA can be detected above background level by qRT-PCR. (C) SOX11 protein expression as determined by
Western Blot analysis. The data shown here is a representative example of three independent experiments.
Sernbo et al. BMC Cancer 2011, 11:405
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Page 7 of 10SOX11 indicates a potential use of epigenetic drugs to
affect cell growth through common cell regulatory path-
ways, controlled by SOX11, and other tumour suppres-
sors that are silenced in EOC. Furthermore, functional
investigations in vitro confirmed a growth regulatory
role for SOX11 in EOC.
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